Deadly Coldrif Cough Syrup: 350 Shocking Violations Found at Tamil Nadu Drug Unit

A shocking investigation has revealed over 350 violations at a pharmaceutical manufacturing unit in Tamil Nadu responsible for producing a deadly cough syrup linked to multiple child deaths in Chhindwara, Madhya Pradesh. The findings have exposed serious lapses in quality control, safety standards, and regulatory oversight within India’s drug manufacturing system.

The Disturbing Discovery

The Tamil Nadu Drugs Control Department recently inspected the pharmaceutical unit located near Sriperumbudur. Officials discovered widespread negligence in hygiene, documentation, and equipment maintenance. The plant, which produced the Coldrif cough syrup, was found operating in violation of Good Manufacturing Practices (GMP).

Inspectors reported that the factory premises were unhygienic — with cracked walls, contaminated containers, and poorly maintained storage areas. Production and packaging activities were conducted without proper sterilization or air filtration systems. In several sections, inspectors found leaking pipes, non-functional equipment, and unsafe use of gas cylinders for heating chemical mixtures.

350 Violations: A Breakdown

According to reports, the Tamil Nadu Drugs Control Department found more than 350 separate violations, including major and critical lapses. These violations ranged from non-compliance with manufacturing protocols to missing quality assurance documentation.

Key violations included:

• Use of raw materials of questionable quality without proper testing.

• Lack of quality control records or standard operating procedures.

• Absence of batch-wise manufacturing documentation.

• Poor maintenance of storage areas, exposing products to contamination.

• Inadequate labeling and failure to display child-safety warnings.

• Use of unverified chemical solvents such as propylene glycol and glycerin.

• No mechanism for product recall or complaint investigation.

Deadly Consequences in Madhya Pradesh

The Coldrif cough syrup manufactured at this Tamil Nadu plant has been directly linked to the deaths of at least 17 children in Chhindwara, Madhya Pradesh. Laboratory tests confirmed the presence of diethylene glycol (DEG) — a toxic industrial chemical used in antifreeze — at dangerously high levels in the syrup.

Diethylene glycol poisoning can cause kidney failure, neurological damage, and death, especially in young children. This tragic incident mirrors several past cases where contaminated syrups have claimed lives in India and abroad.

Factory Sealed, Owner Arrested

Following the discovery, Tamil Nadu authorities immediately sealed the manufacturing facility. The factory owner and key executives were arrested under provisions of the Drugs and Cosmetics Act. The government has also suspended the firm’s manufacturing license and initiated a wider probe into the company’s operations.

Meanwhile, health officials in Madhya Pradesh have banned the sale and distribution of the Coldrif syrup and related products. Nationwide alerts have been issued to trace and recall all remaining stocks from pharmacies and distributors.

A Wake-Up Call for India’s Pharma Industry

The incident has reignited concerns about regulatory oversight in India’s pharmaceutical manufacturing sector. Experts warn that small-scale units often operate with minimal supervision, outdated machinery, and limited staff. While India is a global hub for medicine production, repeated violations threaten its reputation and public safety.

Regulatory authorities have called for:

1. Stricter inspections and surprise audits.

2. Mandatory testing of raw materials before use.

3. Real-time tracking of medicine batches and distribution.

4. Transparency in inspection reports and licensing procedures.

5. Severe penalties for companies found guilty of endangering lives.

Conclusion

The 350 violations at the Tamil Nadu unit serve as a grim reminder of how negligence and weak oversight can lead to tragic consequences. As investigations continue, the government’s response will determine whether meaningful reform follows — or if this becomes yet another forgotten case in India’s long list of preventable pharmaceutical disasters.